<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394913</url>
  </required_header>
  <id_info>
    <org_study_id>ETAEMS0411</org_study_id>
    <nct_id>NCT01394913</nct_id>
  </id_info>
  <brief_title>Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a comparison of safety and efficacy of two etanercept regimens (REUMATOCEPT®
      versus ENBREL®) for treatment of Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      • Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.

      Study design:

        -  Experiment duration: 30 weeks

        -  9 visits (days 0, 14, 42, 70, 98, 126, 154, 182, 210)

        -  Health Assessment Questionnaire (HAQ) evaluation

        -  Disease Activity Score (DAS28) evaluation

        -  Clinical Disease Activity Index (CDAI) evaluation

        -  American College of Rheumatology criteria (ACR) evaluation

        -  Visual Activity Schedule(VAS) evaluation

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study suspended by decision strategically.
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>day 1 to day 210</time_frame>
    <description>Health Assessment Questionnaire (HAQ)
Disease Activity Score (DAS28)
Clinical Disease Activity Index (CDAI)
American College of Rheumatology criteria (ACR)
Visual Activity Schedule(VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>day 1 to day 210</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Reumatocept 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg each week for 30 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg each week for 30 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reumatocept (etanercept)</intervention_name>
    <description>50mg each week for 30 weeks</description>
    <arm_group_label>Reumatocept 25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel (etanercept)</intervention_name>
    <description>50mg each week for 30 weeks</description>
    <arm_group_label>Enbrel 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with clinical diagnosis of moderate to severe rheumatoid arthritis according
             to American College of Rheumatology (ACR) criteria;

          3. Patients with at least 6 swollen joints

          4. Patients with partial response in treatment with methotrexate for 2 months

        Exclusion Criteria:

          1. Pregnancy and Lactation

          2. Patients with uncontrolled hypertension

          3. Patients with other rheumatic disease such as Sjogren syndrome, systemic lupus
             erythematosus or spondyloarthritis

          4. Non-steroidal anti-inflammatory drug in the last 4 weeks

          5. Any pathology or past medical condition that can interfere with this protocol

          6. Patients with immunodeficiency and/or immunosuppressive disease;

          7. Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associação de Assitência à Criança Deficiente</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04038004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

